InspireMD Inc. (NSPR) News
Filter NSPR News Items
NSPR News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
NSPR News Highlights
- For NSPR, its 30 day story count is now at 2.
- Over the past 14 days, the trend for NSPR's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- DEC and NOTE are the most mentioned tickers in articles about NSPR.
Latest NSPR News From Around the Web
Below are the latest news stories about INSPIREMD INC that investors may wish to consider to help them evaluate NSPR as an investment opportunity.
InspireMD Announces Issuance of Key U.S. Patent Covering Its SwitchGuard™ Neuroprotection SystemReflects continued focus on adding intellectual property to support the strategic direction of the Company to provide a complete solution set for the treatment of carotid artery disease and the prevention of strokeTEL AVIV, Israel and MIAMI, Dec. 20, 2023 (GLOBE NEWSWIRE) -- InspireMD (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, announced today the issuance of U.S. Patent No. 11,844,893, titled, “Shunts with Blood Flow Indicators.” |
InspireMD's Gary Roubin Acquires 13% More StockInvestors who take an interest in InspireMD, Inc. ( NASDAQ:NSPR ) should definitely note that insider Gary Roubin... |
InspireMD Announces Strategic Agreement with Jacobs Institute to Execute Early Feasibility Study of CGuard EPS for the Treatment of Acute Stroke Patients with Tandem LesionsStudy to enroll 15 acute stroke patients across three U.S. sitesTEL AVIV, Israel and MIAMI, Nov. 27, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that the company has entered into a strategic agreement with the Jacobs Institute at the State University of New York at Buffalo, and Dr. Adnan Siddiqui, Vice-Chairman and Professor of Neurosurgery, to execute an Early Feasibility St |
InspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call TranscriptInspireMD, Inc. (NASDAQ:NSPR) Q3 2023 Earnings Call Transcript November 6, 2023 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.17. Operator: Good morning. And welcome to the InspireMD Third Quarter of 2023 Earnings Call. Currently, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions]. […] |
InspireMD Inc (NSPR) Reports Q3 2023 Financial Results: CGuard EPS Revenue Increases by 9% ...Positive 30-day results from C-GUARDIANS U.S. IDE clinical trial and CMS' decision to expand CAS coverage contribute to the company's growth |
InspireMD Reports Third Quarter 2023 Financial Results and Provides Business Update- Presented positive 30-day follow-up results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial demonstrating an overall major adverse events rate (DSMI) of 0.95% from procedure through 30 days at the Vascular InterVentional Advances Annual Meeting (VIVA23) – - Announced support for CMS’ final decision expanding coverage of CAS to include both asymptomatic and standard risk patients, significantly expanding the U.S. CAS addressable market – - Generated Q3 2023 CGuar |
InspireMD to Participate in Upcoming November Investor ConferencesTEL AVIV, Israel and MIAMI, Fla., Nov. 02, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for treatment of carotid artery disease and prevention of stroke, today announced that the Marvin Slosman, Chief Executive Officer, will participate in three upcoming investor conferences in November: Wolfe Research Healthcare Conference Wednesday, November 15, 2023 Fireside chat: 12:30pm ET Canaccord Genuity MedTech, Diagnostics, Digi |
InspireMD Presents Positive 30-Day Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial at VIVA23Data demonstrate a low major adverse event rate of 0.95% through 30 days post-procedureTEL AVIV, Israel and MIAMI, Nov. 01, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today presented 30-day results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) clinical trial at the Vascular InterVentional Advances (VIVA) meeting, which is being held October 30 through November 2 in Las Ve |
InspireMD to Report Third Quarter 2023 Financial Results and Provide Corporate Business Update on Monday, November 6th-Conference call and webcast to be held at 8:30 a.m. EST- TEL AVIV, Israel and MIAMI, Oct. 30, 2023 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) device for the treatment of Carotid Artery Disease and stroke prevention, announced today it will report third quarter 2023 financial results on Monday, November 6th, 2023, before the financial markets open. Management will host a conference call and webcast with the investment commun |
InspireMD's (NASDAQ:NSPR) investors will be pleased with their impressive 179% return over the last yearThe most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a company... |